Compass, Inc. Share Price Target ‘$4.15’, now -4.2% Downside Potential

DirectorsTalk Interviews

Compass, Inc. which can be found using ticker (COMP) have now 9 confirmed analysts covering the stock with the consensus suggesting a rating of ‘hold’. The target price High/Low ranges between $6.00 and $3.00 calculating the mean target share price we have $4.15. (at the time of writing). Given that the stocks previous close was at $4.33 this would imply there is a potential downside of -4.2%. It’s also worth noting that there is a 50 day moving average of $3.56 while the 200 day moving average is $3.18. The market cap for the company is 2.13B. The stock price for Affirm Holdings, Inc. is $4.30 USD

The potential market cap would be $2,037,923,773 based on the market consensus.

The company has a dividend yield of 5.95%. Other points of data to note are a P/E ratio of -, revenue per share of $10.46 and a -10.37% return on assets.

Compass, Inc. is a technology-enabled brokerage that provides an end-to-end platform of software, services, and support to helps its residential real estate agents to deliver service to seller and buyer clients. The Company’s platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service, brokerage services and other critical functionalities, all custom-built for the real estate industry and enables its core brokerage services. The platform also uses data, analytics, artificial intelligence and machine learning to deliver recommendations and outcomes for Compass agents and their clients. Agents use its platform to assist home sellers and buyers in listing, marketing, selling and finding homes, as well as through the provision of services, such as title, escrow and mortgage. Its Glide tools include completion of various real estate forms, offers preparation, as well as e-signature and collaboration capabilities.

Share on:
Find more news, interviews, share price & company profile here for:

    Nuformix applies for US Orphan Drug Designation for NXP002 in IPF

    Nuformix has submitted an application to the US FDA for Orphan Drug Designation for tranilast, the active ingredient in its NXP002 inhaled therapy for idiopathic pulmonary fibrosis.

    Dekel Agri-Vision sees record cashew output, higher palm oil prices

    Dekel Agri-Vision has announced a July 2025 update, highlighting record monthly raw cashew nut processing of 533 tonnes at its Tiebissou plant, up 423% from July 2024.

    Diversified Energy delivers strong H1 2025 with Carlyle partnership boost

    Diversified Energy Company posted first-half 2025 results in line with expectations, delivering strong production growth, improved financial metrics, and $152 million in adjusted free cash flow

    EDX Medical Group to complete the development of new pneumonia test

    EDX Medical will partner with the Intensive Care Unit at Cambridge University Hospitals NHS Foundation Trust to support the further advancement of a highly precise test that identifies the DNA or RNA of the microbes that cause lung infection in critically ill patients. 

    Union Jack Oil director increases shareholding

    Union Jack Oil Non-Executive Director Craig Howie has acquired 122,000 shares at 5.075 pence each, raising his total holding to 3,377,000 shares, representing 2.21% of the company’s issued share capital.

    Aptamer Group to host technical development update webinar

    Aptamer will hold a webinar on 14 August 2025 at 6:00 pm BST, led by Chief Scientific Officer Dr David Bunka, to present the latest data and progress across its technical development programmes.

      Search

      Search